Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions

Reuters

2025/06/13

Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions

Innovent Biologics Inc., a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes (T2D), known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09219) on June 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543152182"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543152182\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543152182?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543152182","market":"fut","top_or_hot":-1,"title":"Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a>, a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes (T2D), known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09219) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 09:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a>, a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes (T2D), known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBXF\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09219) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL7Gws5d:1","article_id":"2543152182","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543152182","pubTimestamp":1749776424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent Biologics Inc., a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes , known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","BK1147":"投资银行业与经纪业","01801":"信达生物","01911":"华兴资本控股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念"},"translate_title":"信达生物将在ADA科学会议上展示Mazdutide治疗2型糖尿病的3期临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent Biologics to Present Phase 3 Clinical Trial Results of Mazdutide for Type 2 Diabetes at ADA Scientific Sessions\n    \n\nInnovent Biologics Inc., a leading biopharmaceutical company specializing in oncology, autoimmune, cardiovascular and metabolic, and ophthalmology treatments, has announced the upcoming presentation of multiple clinical study results at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025. Highlighting the event will be the oral presentation of the first Phase 3 study of mazdutide in Chinese adults with Type 2 Diabetes (T2D), known as DREAMS-1, scheduled for June 23. Additionally, numerous exploratory mechanism of action analyses of mazdutide and a preclinical study of the novel antibody-peptide conjugate IBI3030 will be featured in poster presentations on June 22. These presentations aim to further validate the differentiated profile of mazdutide as a next-generation GCG/GLP-1 dual receptor agonist.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09219) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}